A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

Thumbnail Image
Files
A novel polymorphism inABCB1 gene, CYP2B66 andsex predict single-doseefavirenz populationpharmacokinetics inUgandan.pdf (854.33 KB)
Date
2009
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
British journal of clinical pharmacology
Abstract
Efavirenz, a potent antiretroviral agent, is the cornerstone of highly active antiretroviral therapy (HAART), particularly in human immunodeficiency virus (HIV) and tuberculosis co-infected patients being co-treated with rifampicin. Its essential role as an affordable HAART treatment in resource-poor countries is due to its relatively low cost, manageable pill burden and solid efficacy as well as safety documentation
Description
Keywords
ABCB1, CYP2B6, CYP3A5, Efavirenz, Population pharmacokinetics, Ugandans
Citation
Mukonzo, JK (2009). Rö shammar D, Waako P, Andersson M, Fukasawa T, Milani L, et al. A novel polymorphism in ABCB1 gene, CYP2B646 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. British journal of clinical pharmacology , 68 (5), 690-9.
URI
https://nru.uncst.go.ug/xmlui/handle/123456789/339
Collections
Medical and Health Sciences